Table I.
Clinicophathological characteristics of patients with PST triple negative breast cancer.
| Characteristics | n (%) |
|---|---|
| Age (years) | |
| Mean | 49 |
| Range | 33–78 |
| Sex | |
| Female | 16 (100) |
| Histological type | |
| Invasive carcinoma of no special type | 16 (100) |
| TNM stage at initial diagnosis (22) | |
| I | 0 |
| IIA | 4 (25) |
| IIB | 9 (56) |
| IIIA | 0 |
| IIIB | 3 (19) |
| PST regimens | |
| FEC | 2 (13) |
| FEC+PTX | 7 (44) |
| FEC+DTX | 7 (44) |
| Clinical tumor responsea | |
| CR | 4 (25) |
| PR | 10 (63) |
| SD | 1 (6) |
| PD | 1 (6) |
| PST effect | |
| pCR | 3 (19) |
| Non-pCR | 13 (81) |
a
Clinical therapeutic response to PST was evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; PTX, paclitaxel; DTX, docetaxel; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PST, primary systemic therapy; pCR, pathological complete response.